The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model
H. Yoshiji et al., The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model, HEPATOLOGY, 33(4), 2001, pp. 841-847
The vascular endothelial growth factor-A (VEGF-A), also known as the vascul
ar permeability factor (VPF), has been shown to play an important role in m
alignant ascites formation. The effects of VEGF-A are mediated through flt-
1 and kinase insert domain-containing receptor/fetal liver kinase (KDR/Flk-
1) receptors. It has been shown that KDR/Flk-1 is a predominant receptor in
solid hepatocellular carcinoma (HCC) development, but the role of this rec
eptor in hepatic ascites formation has not yet been elucidated. In this stu
dy, we examined the role of KDR/Flk-1 in the murine MH134 hepatic malignant
ascites formation by means of VEGF-A- and KDR/Flk-1-specific neutralizing
antibodies (VEGF-A nAb and KDR/Flk-1 nAb, respectively). The mean volume of
ascites, number of tumor cells in ascites, and the peritoneal capillary pe
rmeability were significantly suppressed by VEGF-A nAb and KDR/Flk-1 nAb tr
eatment. These inhibitory effects of KDR/Flk-1 nAb were more potent than th
ose of VEGF-A nAb, The autophosphorylation of KDR/Flk-1 in the peritoneal w
all was almost completely abolished by KDR/Flk-1 nAb, whereas a certain lev
el of activation was still shown by VEGF-A nAb treatment. Another VEGF-fami
ly, VEGF-C, which also binds KDR/Flk-1,was detected in the ascites. Further
more, in the therapeutic experiment, although both VEGF-A nAb and KDR/Flk-1
nAb prolonged the survival rate of ascites-bearing mice, the latter showed
a more significant impact on the survival of animals. These results sugges
t that KDR/Flk-1 is a major regulator of malignant hepatic ascites formatio
n, and that in addition to VEGF-A, VEGF-C may also be involved in the malig
nant ascites formation via KDR/Flk-1 activation.